article thumbnail

Janssen leads effort to cut waste in digital health devices

pharmaphorum

The project started on 1 October and is scheduled to complete in September 2026. The post Janssen leads effort to cut waste in digital health devices appeared first on. The four devices will be put through their paces in real-world healthcare settings via pilot projects in Norway, Belgium, Slovenia, Spain, and Germany.

Leads 124
article thumbnail

Jazz Pharma uses flying pig for huge grey area DTC

World of DTC Marketing

billion by 2026. This has abuse potential written all over it and could lead to more dangerous health problems. One of the most common complaints people have is “lack of energy” Consumers have turned to energy drinks which was valued at $53.01 billion in 2018, and is expected to grow at a CAGR of 7.20% to reach $86.01

Pharma 181
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may lead to a Comirnaty monopoly

Pharmaceutical Technology

More significantly, the revised contract secures about 70 million vaccine doses every year from 2023 to 2026 for member states, leaving little space in the market for competitors. This deal, therefore, serves as a threat to other vaccine developers with authorisations for distribution in the EU, including Moderna, Novavax, and Sanofi.

Leads 52
article thumbnail

BMS strikes $14bn deal for Karuna Therapeutics

European Pharmaceutical Review

The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. Registrational clinical trials are currently underway evaluating KarXT for the treatment of Alzheimer’s disease psychosis, with data expected in 2026. per share in cash.

article thumbnail

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

Pharmaceutical Technology

NPC is a rare inherited disease resulting from the body's inability to conduct intracellular transport of cholesterol and other lipids, leading to the abnormal accumulation of these substances in various bodily tissues, including brain tissue.

Marketing 122
article thumbnail

Long-term data indicates “significant” potential of aGvHD microbiome treatment

European Pharmaceutical Review

“Beyond the significant impact for patients, this advancement distinguishes our treatment in a context where current options offer only limited benefits and lead to severe complications.

Pharma 98
article thumbnail

Sandoz mobilises critical medicine production in Europe

European Pharmaceutical Review

Sandoz] has the only major remaining vertically-integrated production network for penicillins in Europe” Penicillins are the leading category of antibiotics worldwide, Sandoz highlighted. Launch of these new facilities help to ensure sustainable access to quality antibiotics and spearhead development of biosimilars, Sandoz noted.